Optimization of Acute Treatment in First Episode Schizophrenia

Summary

The study is a multicenter, double-blind, randomized, parallel-group study with first episode schizophrenic patients. During a treatment phase of 8 weeks the patients are treated with Risperidone or Haloperidol. Aim of the project is to compare the effects of the atypical neuroleptic Risperidone with those of the conventional neuroleptic Haloperidol and to evaluate whether the assumed advantages of atypical neuroleptics compared to conventional neuroleptics are also present when both medications are administered in rather low daily dosages (min. 2 mg/d; max. 8 mg/d).

Conditions

• Schizophrenia, First-Episode

Interventions

DRUG

Risperidone, Haloperidol

Sponsors & Collaborators

• Janssen-Cilag Ltd.

  collaborator INDUSTRY

• German Research Network On Schizophrenia

  collaborator NETWORK

• Department of Psychiatry University of Bonn

  collaborator OTHER

• Heinrich-Heine University, Duesseldorf

  collaborator OTHER

• Department of Psychiatry University FU Berlin

  collaborator OTHER

• University of Göttingen

  collaborator OTHER

• University of Cologne

  collaborator OTHER

• Mainz University

  collaborator OTHER

• University Hospital Tuebingen

  collaborator OTHER

• Universität Duisburg-Essen

  collaborator OTHER

• University of Mannheim

  collaborator OTHER

• University of Jena

  collaborator OTHER

• Martin-Luther-Universität Halle-Wittenberg

  collaborator OTHER

• RWTH Aachen University

  collaborator OTHER

• University of Wuerzburg

  collaborator OTHER

• Ludwig-Maximilians - University of Munich

  lead OTHER

Principal Investigators

• Hans-Jürgen Möller, Professor · Department of Psychiatry, Ludwig-Maximilians-University Munich

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2000-11-30

Completion

2004-12-31

Countries

• Germany

Study Locations